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Dear Editor:
Syncope is a serious problem with life-time prevalence of
35% (1). It is estimated that 1 -3% of referrals to emergency
departments and in-patient admissions are due to syncope
(2). The underlying conditions can be cardiac or neurologic.
Considering the completely different circumstances ruling
the encounters with cardiac and neurologic syncope, in re-
cent years many attempts have been made to find the proper
tool for differentiating cardiac and non-cardiac causes of
syncope. The result of which is formation of some clinical
decision rules including San Francisco Syncope Rule (SFSR),
Osservatorio Epidemiologico sulla Sincope nel Lazio (OE-
SIL), Evaluation of Guidelines in Syncope Study (EGSYS),
risk stratification of syncope in the emergency department
(Rose), and Boston Syncope Rules.
The serum marker brain natriuretic peptide (BNP), which
is becoming increasingly established in emergency depart-
ments for diagnosis of acute heart failure, can reflect the
presence of a structural heart disease (3-5). It seems that BNP
could be considered as a screening tool in detection of syn-
cope with cardiac origin.
In a study by Wojtowicz J et al. who evaluated BNP in chil-
dren and adolescents with syncope, there was no significant
difference in terms of BNP level between the syncope and
control groups (6). In contrast, Zhang Q et al. concluded
that serum BNP is helpful in differentiating cardiac (958.78 ±
2443.41 pg/mL) and non-cardiac (31.05 ± 22.64 pg/mL) syn-
cope (7).
Tanimoto K et al. considered the cut-off value of 40 pg/ml for
BNP in differentiating cardiac and non-cardiac syncope and
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found that it had 82% sensitivity and 92% specificity (8). A
significant difference was observed in BNP level of the car-
diac group (514 pg/ml) compared to the non-cardiac ones
(182 pg/ml) in Pfister et al. study (4). It seems that, more re-
search is needed to clarify this relationship and the variables
that might play the role of confounders in a causal inference.
More studies on children are required because there is some
controversy regarding this relationship. Running studies with
accurate methodology, large sample sizes, and in a multi-
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